Abstract There is much interest in in vitro thrombosis systems using exclusively human materials for evaluating new drugs. We have previously developed such a model using a perfusion chamber in which whole blood anticoagulated with low-molecular-weight heparin (LMWH) was circulated over
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n vitro perfusion models for the study of platelet adhesion to the vessel wall have been available for almost 20 years. 13 These models have used rabbit, pig aorta, or human arterial vessels and citrated whole blood. 4 -5 More recently, other perfusion chambers have been developed, allowing the study of platelet adhesion to the extracellular matrix (ECM) of cultured cells or coverslips coated with single adhesive proteins. 6 These procedures in citrated blood have been useful in the understanding of platelet-subendothelium interactions, but they have the inconvenience of not allowing the study of coagulation mechanisms. Weiss et al 7 ' 8 have demonstrated that it is possible to modify the perfusion model in such a way that thrombus and fibrin formation can be measured in native blood. They used this perfu-1 . An exception was the pentasaccharide Org 31550. Only 12% of formed fibrin was deposited at both shear rates. Unlike the other glycosaminoglycans, the pentasaccharide was unable to inhibit thrombin formation in the circulating blood when tissue factor was present in the matrix. The low-molecular-weight heparin(oid)s differed considerably in the flow model. These differences were not predicted by their anticoagulant activity in the test tube. Orgaran is most suitable for studying platelet adhesion under flow conditions in which no tissue factor is present because it does not cause platelet clumping in the circulating blood. The pentasaccharide Org 31550 showed the weakest inhibition of thrombin generation and may be the best anticoagulant for studying thrombosis when a single-pass perfusion system is used. The use of native blood perfusions as an ex vivo thrombosis model has a number of practical disadvantages. The amount of blood required is usually too large to perform serial or comparative experiments. However, the main drawback is that the addition of drugs or monoclonal antibodies is not possible. These problems have limited the experimental approach with native blood to a considerable extent. Because there is a serious need for an in vitro thrombosis model using exclusively human components, we have tried to adapt the perfusion system to this purpose. In a previous article, our group showed that a low-molecular-weight heparin (LMWH) prevents the activation of blood coagulation in vitro for prolonged periods of time, while it does not interfere with the coagulation process that is initiated when anticoagulated blood is exposed to phorbol-stimulated endothelial cell matrices under flow conditions, leading to platelet thrombi and fibrin deposition. The main objective of the present work was to study the effects of flow and different anticoagulants on platelet adhesion, thrombus formation, and fibrin deposition in this thrombosis model. The anticoagulants studied were three LMWHs, a synthetic derivative of the pentasaccharide containing the minimal binding region of heparin to antithrombin III, 10 and unfractionated heparin (UFH). Table 1 shows the products studied. All of them were kindly provided by their manufacturers. Fragmin and Fraxiparine are obtained from porcine mucosal heparin by nitrous acid depolymerization and subsequent chromatographic purification. Orgaran is a low-molecular-weight heparinoid produced directly from animal intestinal mucosa and is composed of a mixture of dermatan sulfate, heparan sulfate, and chondroitin sulfate; in contrast to UFH and other LMWHs, it contains galactosamine in its molecule. Org 31550 is a chemically synthesized derivative of the natural pentasaccharide; it contains an extra 3-O-sulfate at one of the glucosamine moieties and possesses a higher specific anti-Xa activity than the natural pentasaccharide (1230 anti-Xa U/mg versus 700)." UFH was produced from porcine intestinal mucosa.
Methods

Agents Tested
Perfusion Chamber and Adhesive Surfaces
Perfusions under steady flow were carried out with a parallel-plate perfusion chamber described and characterized in detail previously. 6 This perfusion chamber contains two circular plugs on which glass or Thermanox (Lab-Tek Division, Miles Laboratories) coverslips are mounted. The coverslip surface in our experiments was covered with ECMs of endothelial cells, which were exposed to the flowing blood in the perfusion chamber.
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords according to the method originally described by Jaffe et al 12 with minor modifications.
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Cells were identified by their typical morphological characteristics. HUVECs of the second passage subcultured on gelatincoated coverslips were used for the experiments. Before the cells were seeded, gelatin was fixed with 0.5% glutardialdehyde. Cell monolayers were grown to confluence in 5 to 7 days (50 000 cells per cm 2 ). For some experiments cells were stimulated for 16 hours with 4a-phorbol 12-myristate 13-acetate (PMA, Sigma Chemical Co) dissolved in dimethyl sulfoxide and next diluted 1:1000 (vol/vol) in cell culture medium, resulting in a final concentration of 20 ng/mL PMA. PMA stimulation of endothelial cells leads to increased tissue factor production, and part of this tissue factor is present in the ECM. 9 On the day of the perfusion studies, ECM was obtained by removal of the endothelial cells by exposure to 0.1 mol/L NH4OH at room temperature for 5 minutes. Isolated matrices were washed three times with phosphate-buffered saline (PBS) (1:10 [vol/vol] 0.1 mol/L sodium phosphate buffer, pH 7.4, in 0.15 mol/L NaCl) and kept at 4°C in this buffer until use.
Blood Collection and Anticoagulation
All test compounds were diluted in saline to concentrations 10 times higher than those desired in whole blood. Blood from healthy human donors who denied taking medication influencing platelet function in the previous week was collected by a clean venipuncture from an antecubital vein in 1:10 (vol/vol) of the glycosaminoglycan-saline solution. The blood from each donor was anticoagulated with the five agents tested. Results of each donor are mean values of two separate perfusion runs.
For determination of the required anticoagulant concentration for the perfusion experiments, blood was collected in a low concentration of each product. Subsequently, blood was subdivided into containers, to which further amounts of the anticoagulants had been added, and kept at room temperature for 3 hours. At the time of collection and every subsequent hour, a sample was taken for fibrinopeptide A (FPA) assay.
14 Perfusions Fifteen-milliliter perfusates, prewarmed for 5 minutes at 37°C, were recirculated for 5 minutes. Different wall shear rates were obtained by varying flow rate and/or chamber height.
6 After perfusion the system was thoroughly rinsed with 30 mL of HEPES-buffered saline (10 mmol/L HEPES, 0.15 mol/L NaCl, pH 7.4), and the coverslip was removed from the chamber. Before and immediately after perfusion, samples were collected from the reservoir for the assay of FPA and platelet microaggregate formation. In some experiments blood in the reservoir was kept at 37°C after the perfusion, and samples for FPA assay were taken at 5 and 10 minutes.
For en face evaluation perfused coverslips were fixed with 0.5% glutardialdehyde (Fluka Chemie) in PBS and stained with May-Grunwald/Giemsa. When the amount of fibrin deposited on coverslips interfered with the evaluation of platelet coverage with this conventional staining technique, ie, when tissue factor was present on the matrix and perfusions were carried out at a low shear rate, perfused coverslips were fixed with 2% paraformaldehyde and stained with an indirect immunoperoxidase staining method. 15 In short, fixed coverslips were incubated in turn with glycine, hydrogen peroxide, and normal rabbit serum. Subsequently, they were incubated with a mouse anti-glycoprotein Ib antibody (kindly supplied by Dr M. Metzelaar from our department), rinsed, and incubated with a rabbit anti-mouse immunoglobulin antibody labeled with horseradish peroxidase (Dakopatts). Finally, bound peroxidase was detected by incubation with 3,3-diaminobenzidine (Sigma) in PBS to which 0.025% H 2 O 2 was added immediately before incubation. Cobalt and nickel salts were also added to the solution to yield a more intense black reaction product. Platelet deposition was determined with a light microscope connected to an image analyzer (40-10 Image Analyzer, Analytical Measuring Systems Ltd) as described before 16 and are expressed as the percentage of the surface covered by platelets. A minimum of 30 randomly selected areas of each coverslip were evaluated, and the result of duplicate coverslips was averaged.
For cross-section evaluation, perfused Thermanox coverslips were fixed with 0.5% glutardialdehyde and subsequently exposed to osmium tetroxide as postfixation. After dehydration by washing with increasing concentrations of ethanol, the coverslips were covered with epoxy resin, as published.
17 After heat polymerization, the epoxy resin with the embedded matrix and the adhered platelets were separated from the coverslip by thermoshock. One-micrometer-thick sections of the epoxy resin-embedded matrix were cut and stained with methylene blue and basic fuchsin and evaluated with a light microscope connected to the image analyzer. Results are presented as the percentage of the surface covered by platelets and percentage of the surface covered by aggregates (<5 ^m, 5 to 10 fim, and >10 /im in height, respectively).
Single-Platelet Disappearance
The extent of platelet microaggregate formation during recirculation in the perfusion system was assessed using a modification of Frojmovic's method. 1819 In short, after perfusion 100-jiL blood samples were added to 900 jiL of either 0.5% glutardialdehyde or 0.178% EDTA (Fluka AG) in PBS. Both samples were subsequently counted in a Platelet Analyzer 810 (Baker Instruments) with apertures set between 3.2 and 16 femtoliters. Single-platelet disappearance (SPD) was expressed as a percentage and calculated as
ibrin Deposition
Fibrin formation on perfused Thermanox coverslips was quantified using radiolabeled fibrinogen ( l25 I-Fg; molar ratio of 123 I to Fg, 0.5; specific activity, 320xl0 6 cpm/mg; more than 99% clottable). Fibrinogen concentration present in the perfusate was measured according to Clauss, 20 and l23 I-Fg was added to the perfusates in a 1000:1 molar ratio of native fibrinogen to 12! I-Fg. After perfusion, coverslips were rinsed with HEPES-buffered saline, and the part of the coverslip exposed to flowing blood was assayed for radioactivity.
Fibrinopeptide A Assays
FPA was assayed using a radioimmunoassay kit (BykSangtec) according to the manufacturer's instructions. Blood samples (900 fiL) were collected before and after perfusion experiments and added to the 100 -jtL anticoagulant mixture provided in the kit. FPA values were expressed in picomoles per milliliter of plasma. Samples with high FPA concentrations were diluted with a plasma protein solution (CLB) with an FPA level less than 0.62 pmol/mL. FPA generation was calculated from the increase in FPA concentration before and after perfusion. All samples were assayed in duplicate, and the results were averaged. The amount of fibrin molecules formed was calculated from the FPA produced and compared with the amount of fibrin deposited on the perfused area. One mole- •Institute Choay anti-Xa units.
cule of fibrinogen was assumed to yield two molecules of FPA, and the total ECM surface exposed to the flow was 4.2 cm 2 .
Statistical Analysis
One-factor repeated-measures ANOVA followed by the Bonferroni method of multiple comparisons was used to compare groups of means of the studied parameters obtained for the tested glycosaminoglycans. A .05 significance level was used. Linear regression adjusted by means of the least-squares method was used to study correlation between variables.
Results
Selection of Optimal Anticoagulant Concentrations
The potency of heparins is expressed as anti-Xa activity, but it has been recognized that this is an unsatisfactory reflection of the antithrombotic potency of LMWHs. 21 ' 22 Because we wanted to use the lowest concentration of anticoagulant possible, we first determined the minimal amount required for complete inhibition of thrombin activity in blood kept at room temperature for 3 hours. FPA was taken as an indicator of generated thrombin. Table 2 shows the required concentrations in terms of anti-Xa activity as provided by the manufacturer and on a weight basis. Fragmin and Fraxiparine were almost equally effective on a weight basis but differ in the anti-Xa activity expressed according to the manufacturer. Much larger quantities in terms of weight were required for Orgaran. Large quantities in terms of anti-Xa activity were required for the pentasaccharide Org 31550.
Platelet Deposition
The direct effect of the glycosaminoglycans on platelet adhesion was studied in an experiment in which blood was circulated over nonstimulated ECM at 1600 s" 1 . These studies could not be performed with the pentasaccharide Org 31550 because the low amount of tissue factor present in the nonstimulated ECM was already sufficient to produce thrombin generation, which caused aggregate formation. Fig 1 shows the platelet coverage as a percentage of the exposed surface correlated to the microaggregate formation in the circulated blood expressed as SPD for each LMWH studied. Orgaran gave a significantly higher platelet coverage (P=.OO9) compared with the other test compounds. Differences in SPD were statistically significant only when Orgaran was compared with Fragmin (f=.O2). SPD and platelet coverage in perfusions performed under these conditions showed a statistically significant inverse linear correlation (r= -.526, P=.Q\). The correlation was even more significant when only blood platelet count in glutardialdehyde and platelet coverage were considered for each perfusion run (r=-0.585, / ) =.003). To establish the influence of the test compounds on platelet aggregate formation, we carried out perfusions over PMA-stimulated ECM at 1600 s" 1 , and perfused coverslips were evaluated after embedding using cross sections as described in "Methods." Table 3 summarizes the results. Coverslips perfused with blood anticoagulated with Org 31550 could not be evaluated because an almost continuous layer of fibrin was present even at a high shear rate and interfered with the measurements. The overall coverage, the coverage by aggregates less than 5 /xm, and that by aggregates between 5 and 10 /xm in height were similar for all tested compounds. Only the percentage of coverage with aggregates larger than 10 /mi differed: UFH and Orgaran showed lower values than Fragmin and Fraxiparine. The differences observed were statistically significant only when UFH and Orgaran were compared with Fraxiparine (P=.O4). Under these conditions, differences observed in SPD values with Fragmin, Fraxiparine, Orgaran, and UFH were not statistically significant. Org 31550 gave a significantly higher SPD compared with the other heparins tested (P<.&2). (SPD values: Fragmin, 29.0±3.3; Fraxiparine, 24.4±3.9; Orgaran, 22.5±3.5; UFH, 23.4±6.3; and Org 31550, 49.3.0±7.4; mean±SEM, n=3). In perfusions performed over PMA-stimulated ECM at 300 s" 1 the evaluation was performed en face using an indirect immunoperoxidase staining method to avoid staining problems because of the high fibrin deposition. Under these conditions platelet coverage of the surface was also similar for all the glycosaminoglycans tested (Fragmin, 11.3±1.3; Fraxiparine, 12.4±1.6; Orgaran, 15.2±1.2; UFH, 12.9±2.1; Org 31550, 11.6 + 2.0; mean±SEM, n=4). Table 4 shows the amount of fibrin deposited on coverslips and the FPA generation after perfusion at 300 and 1600 s~\ The amount of fibrin observed after circulation of UFH-anticoagulated blood at both shear rates was negligible. Light microscopy and scanning electron microscopy (Fig 2) showed no fibrin, and the observed values probably reveal the background of radiolabeled fibrinogen associated with the matrix and/or platelets. Also, FPA generation was insignificant with UFH-anticoagulated blood. In contrast, fibrin was formed on the perfused coverslip with the other tested glycosaminoglycans, and the amount differed depending on the compound used as anticoagulant and the shear rate.
Fibrin Formation
At a shear rate of 300 s~', Org 31550 gave the largest amount of deposited fibrin, followed by Fraxiparine and Fragmin. Orgaran inhibited fibrin deposition on the perfused area to a larger extent. The differences observed among mean values were highly statistically significant (P<.001).
At a shear rate of 1600 s" 1 , the amount of deposited fibrin was lower than at 300 s" 1 . For Org 31550 and UFH, this reduction did not reach statistical significance. A significant reduction was seen for Fragmin (85%), Orgaran (85%), and Fraxiparine (81%).
The differences in FPA generated at 300 or 1600 s" 1
were not significant for the tested products. FPA generation stopped at the end of the perfusion. Org 31550 was an exception because FPA levels 10 minutes after perfusion were more than 30% higher than directly after perfusion. The theoretical amount of fibrin formed during perfusion was calculated from the generated FPA, and this value was compared with the total amount of deposited fibrin as quantified by radiolabeled fibrinogen. Table 5 shows the results. When perfusions were carried out at 300 s" 1 , for UFH approximately 100% of the calculated fibrin formed was deposited on the perfused surface. For Fragmin 93% of calculated fibrin was deposited, and for Fraxiparine approximately 70%. For Orgaran a discordant result was obtained: three times as much fibrin was deposited as the calculated amount formed in the fluid phase. For Org 31550 only 12.3% of the fibrin generated during perfusion was found on the perfused ECM.
In perfusions performed for 5 minutes at 1600 s" 1 , the fibrin deposited on the perfused surface as a percentage of the calculated fibrin formed was in the same range for all the test compounds, ie, 5% for Fragmin, 9% for Fraxiparine, 12% for Orgaran, 10% for Org 31550, and 11% for UFH. These values are much lower than those obtained at 300 s" 1 . Org 31550 was an exception; for this anticoagulant the values were in the same range at 300 and 1600 s" 1 . For UFH there was a reduction of 65% although no visible fibrin formation was observed at either 300 or 1600 s' 1 .
Discussion
In the present study we have compared various glycosaminoglycans for their suitability in an in vitro thrombosis model. In this model anticoagulated blood is recirculated through a rectangular perfusion chamber over coverslips coated with endothelial cell matrix exposed under standardized conditions. Tissue factor in the matrix is induced by culturing the umbilical vein endothelial cells in the presence of PMA. 7 The method is useful for detecting modifications in platelet adhesion, thrombus formation, and fibrin deposition. We found differences among the glycosaminoglycans that were not predicted by their anticoagulant profile in the test tube. The problem in comparing various LMWHs is that the anti-Xa activity, as provided by the manufacturer, is not a good reflection of the total anticoagulant activity of the heparin. We decided to use the lowest concentration of the anticoagulant that prevented thrombin formation in whole blood for at least 3 hours of storage at room temperature in polystyrene tubes. This arbitrary concentration was also selected for practical reasons because it allowed us to perform perfusion studies in which thrombin formation was induced by tissue factor present in the actual perfusion chamber.
As a first step we determined the effect of glycosaminoglycans on platelet adhesion. Such studies could not be performed for Org 31550. Even when no tissue factor was demonstrated with our usual techniques, endothelial cell matrix already induced local thrombin generation and aggregate formation in blood anticoagulated with Org 31550, preventing the determination of platelet adhesion. For the other glycosaminoglycans, similar platelet adhesion was seen, with the exception of Orgaran, which showed significantly higher adhesion. This is probably not due to a direct effect on platelet adhesion. A linear inverse correlation existed between the degree of microaggregate formation in the recirculating blood and platelet adhesion. It is therefore likely that the increased adhesion found for Orgaran is due to this lower microaggregate formation. Microaggregate formation in the recirculating perfusion system is probably due to small amounts of ADP released by red cells damaged in the roller pump, 23 and it is likely that the microaggregation is enhanced by some heparins. Orgaran does not have this enhancing effect, 24 in good agreement with the clinical observation that Orgaran can often be used in patients with heparin-induced thrombocytopenia. 25 Platelet aggregation was studied in perfusions over PMA-stimulated ECM at 300 and 1600 s" 1 . Under such conditions there was no difference in platelet coverage. It is possible that local thrombin generation had an effect on platelet deposition that would cancel any effect of the different glycosaminoglycans on microaggregate formation in circulating blood. Cross-sectioned evaluation of perfusions carried out at 1600 s" 1 allowed us to quantify aggregate sizes. Data obtained showed that platelet aggregate formation with Orgaran and unfractionated heparin were approximately equivalent, but there was an increase in large aggregates when Fraxiparine was used. A similar trend was observed with Fragmin, although differences in this case did not reach statistical significance. The increased aggregate formation observed should be attributed to local thrombin formation, as has been demonstrated by Zwaginga et al. 9 The glycosaminoglycans studied differed strongly in their ability to inhibit thrombin formation, 26 as reflected by the FPA levels at the end of perfusion. Very high FPA levels were found with Org 31550; in addition, in contrast to the other glycosaminoglycans, these values continued to increase after the end of the perfusion. This indicates that thrombin formation also occurred in the fluid phase, once it had started by the presence of tissue factor in the system. Thrombin generation when Fraxiparine and Orgaran are used is a local event, as has been demonstrated previously for Fragmin. 9 The values found for Fraxiparine were much lower than for Org 31550, but they were significantly higher than those found with Fragmin, and the latter were almost five times those found with Orgaran (Table 4) . The low values found with UFH indicate that almost no thrombin generation had occurred in the perfusion chamber with this anticoagulant.
Comparison of FPA generation data found no significant differences at 300 and 1600 s" 1 . There was an increase at 1600 s" 1 in the case of Orgaran, but this was not significant because of the wide scatter. These results are at variance with the observations of Weiss et al, 8 who found a shear rate-dependent decrease in FPA generation when they perfused native blood through an annular perfusion chamber with a rabbit aorta as vessel wall. We think that this discrepancy may be caused by differences in the systems used. Studies with purified systems performed by Nemerson and Turitto 27 have indicated an increase rather than a decrease in enzyme activities of the coagulation system with an increase in shear rate.
The differences between glycosaminoglycans in thrombin generation as indicated by FPA levels were reflected in the quantities of fibrin found at 300 s" 1 (Table 4) . By far the highest amount was found with Org 31550. With Fraxiparine a lower amount was found, with Fragmin the level was again lower, and with Orgaran there was about half the amount found with Fragmin. With UFH, no fibrin was found on the surface; the small amount of radioactivity associated with the Thermanox coverslip must be attributed to bound fibrinogen, as was evidenced by scanning electron microscopy. Fibrin deposition was much less at 1600 s" 1 with all the tested compounds, with the exception of Org 31550. In the latter case a certain decrease in fibrin deposition seemed to occur, but this difference did not reach statistical significance. A shear rate dependence for fibrin deposition has been reported by other authors. This correlation has been related to increased removal of fibrin monomers at high shear rate that hampers polymerization of the fibrin network.
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The amount of fibrin formed in the perfusion system could be estimated on the basis of the amount of FPA formed during the perfusion (Table 5) . When these data were compared with the amount that was actually measured on the Thermanox coverslips by radiolabeled fibrinogen in parallel experiments, similar figures were found for all glycosaminoglycans at 1600 s" 1 : approximately 10% of the fibrin that had formed was deposited locally on the surface of the coverslip. The same comparison was made at 300 s" 1 . With Fragmin and Fraxiparine 70% to 90% of the formed fibrin was deposited on the coverslip. For Org 31550 this was only 10% of the total amount formed. A discordant result was observed with Orgaran. The amount of radiolabeled fibrin found on the coverslip in this case was higher than the amount of fibrin that had formed. This must indicate that some fibrinogen had been deposited on the coverslip as well, arguing in favor of the formation of fibrinogen-fibrin complexes. 30 There is some evidence that the relatively high concentrations of glycosaminoglycans used for these experiments may cause the formation of such fibrinogen-fibrin complexes. 31 -32 In the present study we have compared the effect of various glycosaminoglycans on platelet deposition, thrombus formation, and fibrin deposition under flow conditions in the in vitro thrombosis model. These studies lead to the following conclusions: the pentasaccharide Org 31550 is unsuited in preventing thrombin generation in a system in which tissue factor is present. Among the other LMWH(oid)s, Orgaran takes a special position. It has a more potent antithrombotic effect than Fraxiparine or Fragmin. This high antithrombotic potential may be due to the presence of dermatan sulfate, 33 because it has recently been demonstrated that dermatan sulfate-heparin cofactor II complexes are able to inhibit thrombin adsorbed to fibrin, 34 whereas antithrombin III-heparin complexes cannot accomplish this goal. 35 -36 The relatively high fibrin deposition observed in the presence of Orgaran at a low shear rate is probably an artifact of the high anticoagulant concentrations used in our model. The antithrombotic profiles of action of Fragmin and Fraxiparine in this system were basically similar, with perhaps a lower antithrombotic potential for Fraxiparine. Similar findings have been reported by other authors 26 and could be explained by differences in the anti-IIa activity between them. UFH at a concentration of 5 IU/mL was able to completely inhibit thrombin formation on a tissue factor-containing endothelial cell matrix.
The in vitro studies related here indicate that Orgaran is the most suitable anticoagulant for studying platelet adhesion while maintaining in plasma the concentration of divalent cations because it does not cause platelet clumping. The pentasaccharide Org 31550 is the most suitable anticoagulant when maximal thrombin formation is desired. It has the disadvantage that thrombin formation continues in the circulating blood. This makes it unsuitable for use in a thrombosis model with recirculating blood. Fraxiparine is then the most suitable anticoagulant, but the difference with Fragmin is not large.
